pubs.acs.org/joc

## A Facile Asymmetric Synthesis of Either Enantiomer of 2-Substituted Pyrrolidines

Leleti Rajender Reddy,\* Sonia G. Das,<sup>†</sup> Yugang Liu, and Mahavir Prashad

Chemical Research and Development, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936. <sup>†</sup>Current address: Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455.

rajender.leleti@novartis.com

Received January 4, 2010



A new and general method for asymmetric synthesis of either enantiomer of 2-substituted pyrrolidines from a single starting material is described. Reductive cyclization of  $(S_S)$ - $\gamma$ -chloro-*N*-tertbutanesulfinyl ketimines with LiBHEt<sub>3</sub> in THF at -78 to 23 °C afforded ( $S_S, R$ )-N-tert-butanesulfinyl-2-substituted pyrrolidines in excellent yields (88–98%) and with high diastereoselectivity (99:1). The diastereoselectivity is controlled effectively by the choice of reducing agent. Thus, the corresponding epimers of  $(S_{5},S)$ -2-substituted pyrrolidines were synthesized in good yields (87-98%) and with high diastereoslectivity (1:99) by simply switching the reducing agent from LiBHEt<sub>3</sub> to DIBAL-H/LiHMDS. Deprotection of *N-tert*-butanesulfinyl-2-substituted pyrrolidines using 4 N HCl in dioxane and MeOH gave the corresponding enantiomers of 2-substituted pyrrolidines in quantative yield. This method was found to be effective for a variety of substrates including aromatic, heteroaromatic, and aliphatic substituents. Extension of this methodology to the formation of 2-substituted piperidines is also illustrated. Reductive cyclization of  $(S_s)$ - $\delta$ -chloro-*N-tert*-butanesulfinyl ketimine with LiBHEt<sub>3</sub> in THF at -78 to 23 °C or DIBAL-H/LiHMDS in toluene at -78 to 0 °C afforded the  $(S_S, R)$ -N-tert-butanesulfinyl-2-substituted piperidines in excellent yield (98%) and with high diastereoselectivity (99:1) or  $(S_{S_s}S)$ -*N-tert*-butanesulfinyl-2substituted piperidines in good yield (98%) and with high diastereoselectivity (1:99), respectively.

#### Introduction

Enantiomerically pure 2-substituted pyrrolidines are ubiquitous structural motifs found in a wide variety of natural products<sup>1-3</sup> and pharmaceutical drugs.<sup>4–12</sup> Over 4000

**2236** J. Org. Chem. **2010**, 75, 2236–2246

compounds containing this pharmacophore are currently in advanced stages of biological testing.<sup>13</sup> In addition, these compounds are effective chiral controllers and thus play an important role in asymmetric synthesis.<sup>14</sup> As a result, the

Published on Web 03/04/2010

DOI: 10.1021/jo902710s © 2010 American Chemical Society

<sup>(1)</sup> Elbein, A.; Molyneux, R. I. Alkaloids, Chemical and Biological Perspectives; John Wiley: New York, 1990.

<sup>(2)</sup> Chris, V. G.; Karl, A. S. Angew. Chem., Int. Ed. 2007, 46, 8748–8758.
(3) The Alkaloids: Chemistry and Biology; Cordell, G.A., Ed.; Academic Press: San Diego, 2000; Vol. 54.

<sup>(4)</sup> Elliott, R. L.; Ryther, K. B.; Anderson, D. J.; Piattoni-Kaplan, M.; Kuntzweiler, T. A.; Donnelly-Roberts, D.; Arneric, S. P.; Holladay, M. W. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 2703–2708.

<sup>(5)</sup> Jin, J.; Dhanak, D.; Knight, S. D.; Widdowson, K.; Aiyar, N.; Naselsky, D.; Sarau, H. M.; Foley, J. J.; Schmidt, D. B.; Bennett, C. D.; Wang, B.; Warren, G. L.; Moore, M. L.; Keenan, R. M.; Rivero, R. A.; Douglas, S. A. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3229–3232.

<sup>(6)</sup> Corbett, J. W.; Dirico, K.; Song, W.; Boscoe, B. P.; Doran, S. D.; Boyer, D.; Qiu, X.; Ammirati, M.; VanVolkenburg, M. A.; McPherson, R. K.; Parker, J. C.; Cox, E. D. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 6707– 6713.

<sup>(7)</sup> Elliott, R. L.; Kopecka, H.; Lin, N.-H.; He, Y.; Garvey, D. S. Synthesis **1995**, *1995*, 772–774.

<sup>(8)</sup> Hubbard, R. D.; Dickerson, S. H.; Emerson, H. K.; Griffin, R. J.; Reno, M. J.; Hornberger, K. R.; Rusnak, D. W.; Wood, E. R.; Uehling, D. E.; Waterson, A. G. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5738–5740.

<sup>(9)</sup> Li, Q.; Wang, W.; Berst, K. B.; Claiborne, A.; Hasvold, L.; Raye, K.; Tufano, M.; Nilius, A.; Shen, L. L.; Flamm, R.; Alder, J.; Marsh, K.; Crowell, D.; Chu, D. T. W.; Plattner, J. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 1953–1958.

#### SCHEME 1



synthesis of these compounds has been an active area of research. Known synthetic methods of these privileged structures suffer from either long synthetic sequences, low yields, lack of generality, or modest selectivity.15,16 The classical approach to obtain enantiomerically pure 2-substitued pyrrolidines is by resolution of the racemate via diastereoselective salt formation. However, the maximum theoretical yield for resolution is only 50%. Campos et al. have reported<sup>17</sup> an elegant method for asymmetric synthesis of 2-substituted pyrrolidines in a highly enantioselective manner. This method employs (-)-sparteine mediated enantioselective lithiation of N-Boc-pyrrolidine, followed by transmetalation and Pd-catalyzed Negishi coupling. This method is limited to the synthesis of (R)-aryl pyrrolidines due to the lack of inexpensive alternatives for (+)-sparteine.<sup>21</sup> In addition, it utilizes *s*-BuLi, which is a pyrophoric liquid and restricted from use on a large scale.<sup>18</sup> Recently, we reported<sup>19</sup> an asymmetric synthesis of 2-substituted pyrrolidines by addition of Grignard reagents to  $\gamma$ -chloro *N*-tertbutanesulfinyl aldimine followed by base-catalyzed cyclization. This method provides either enantiomer of 2-substituted pyrrolidines by changing the chiral starting material. Thus, development of an asymmetric synthesis to provide either enantiomer of 2-substituted pyrrolidines from the same starting material still remains an elusive challenge. We reasoned that a direct method to access either enantiomer of 2-substituted pyrrolidines would be via asymmetric reductive cyclization of y-chloro-N-tert-butanesulfinyl ketimines 3, and this asymmetric reductive cyclization of 3 to either diastereomers of 2-substituted pyrrolidines has not been described to our knowledge.<sup>20</sup> Herein, we report a versatile and practical method for diastereoselective reductive cyclization of  $(S_S)$ - $\gamma$ -chlorinated *N*-tert-butanesulfinyl ketimines (3) to give either diastereomer of 2-substituted pyrrolidines (4 or 5) in a single step with high yields (Scheme 1). The tert-butanesulfinyl group not only induces excellent diastereoselectivity but also serves as an efficient low molecular weight protecting group for the nitrogen for future modifications of the 2-substituted pyrrolidines, if needed.

SCHEME 2. Synthesis of Chlorinated *N-tert*-Butanesulfinyl Ketimines  $(S_S)$ -3a-3p



#### **Results and Discussion**

Synthesis of  $\gamma$ -Chlorinated N-tert-Butanesulfinyl Ketimines  $(S_s)$ -3a-3p. Two methodologies were investigated for the synthesis of  $\gamma$ -chlorinated *N*-tert-butanesulfinyl ketimines  $(S_S)$ -3a-3p by condensation of appropriate ketones 6a-6p<sup>21</sup> with (S)-tert-butanesulfinamide<sup>22</sup> 7 (Scheme 2). An initial attempt to synthesize 3a under heterogeneous conditions<sup>23</sup> using pyridinium *p*-toluenesulfonate as a catalyst and magnesium sulfate as a water scavenger was unsuccessful. However, a subsequent trial using homogeneous conditions<sup>24</sup> that utilized Ti(OEt)<sub>4</sub> as both a Lewis acid and a water scavenger furnished 3a in 90% yield. Since this approach was straightforward and provided 3a with excellent yields, it was employed to prepare aryl sulfinyl ketimines 3a-3i, heteroaryl sulfinyl ketimine 3j, and aliphatic sulfinyl ketimines 3k and 3p. In the same way, the  $\delta$ -chlorinated *N-tert*-butanesulfinyl ketimine  $(S_S)$ -**3m**,  $\varepsilon$ -chlorinated *N-tert*-butanesulfinyl ketimine ( $S_S$ )-**3n**,  $\zeta$ -chlorinated *N-tert*butanesulfinyl ketimine  $(S_S)$ -30, and dechlorinated *N*-tertbutanesulfinyl ketimine  $(S_S)$ -3p were synthesized via condensation of (S)-tert-butanesulfinamide 7 with ketones 6m-6p, respectively. In all cases, the products were isolated in analytically pure form by extractive workup followed by flash chromatography. <sup>1</sup>H NMR analysis revealed that sulfinyl ketimines 3a-3p existed solely as the (E)-isomer,

(20) Colyer, J. T.; Andersen, N. G.; Tedrow, J. S.; Soukup, T. S.; Faul, M. M. *The J. Org. Chem.* **2006**, *71*, 6859–6862.

(21) Ketones are commercially available from several companies.

(22) Both  $(S_S)$ -tert-butanesulfinamide and  $(S_S)$ -tert-butanesulfinamide are readily available commercially from various companies (\$1800/kg).

(23) Féi, Z.; Wu, Q.; Zhang, F.; Cao, Y.; Liu, C.; Shieh, W.-C.; Xue, S.; McKenna, J.; Prasad, K.; Prashad, M.; Baeschlin, D.; Namoto, K. J. Org. Chem. 2008, 73, 9016–9021.

(24) Ellman, J. A.; Owens, T. D.; Tang, T. P. Acc. Chem. Res. 2002, 35, 984–995.

<sup>(10)</sup> Winn, M.; von Geldern, T. W.; Opgenorth, T. J.; Jae, H.-S.; Tasker,
A. S.; Boyd, S. A.; Kester, J. A.; Mantei, R. A.; Bal, R.; Sorensen, B. K.;
Wu-Wong, J. R.; Chiou, W. J.; Dixon, D. B.; Novosad, E. I.; Hernandez, L.;
Marsh, K. C. J. Med. Chem. 1996, 39, 1039–1048.

<sup>(11)</sup> Xue, C.-B.; Chen, X.-T.; He, X.; Roderick, J.; Corbett, R. L.; Ghavimi, B.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Ribadeneira, M. D.; Vaddi, K.; Trzaskos, J.; Newton, R. C.; Duan, J. J. W.; Decicco, C. P. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 4453–4459.

<sup>(12)</sup> Lin, N.-H.; Carrera, G. M.; Anderson, D. J. J. Med. Chem. 2002, 37, 3542–3553.

<sup>(13)</sup> MDL Drug Data Report; M.I.S., Inc.: San Leandro, CA, 2009.

<sup>(14)</sup> Whitesell, J. K. Chem. Rev. 2002, 89, 1581–1590.

<sup>(15)</sup> Brinner, K. M.; Ellman, J. A. Org. Biomol. Chem. 2005, 3, 2109–2113.

<sup>(16)</sup> Wu, S.; Lee, S.; Beak, P. J. Am. Chem. Soc. 1996, 118, 715-721.

<sup>(17)</sup> Campos, K. R.; Klapars, A.; Waldman, J. H.; Dormer, P. G.; Chen, C.-y. J. Am. Chem. Soc. 2006, 128, 3538–3539.

<sup>(18) (</sup>a) Anderson, N. G. Practical Process Research & Development; Academic Press: San Diego, 2000. (b) Repic, O. Principles of Process Research and Chemical Development in the Pharmaceutical Industry; John Wiley & Sons, Inc.: New York, 1998.

<sup>(19)</sup> Reddy, L. R.; Prashad, M. Chem. Commun. 2010, 222.

SCHEME 3. Asymmetric Reductive Cyclization of  $\gamma$ -Chlorinated *N*-tert-Butanesulfinyl Ketimine ( $S_S$ )-3a by using LiBHEt<sub>3</sub>



and the corresponding (Z)-sulfinyl ketimines were not observed.

Asymmetric Reductive Cyclization of  $\gamma$ -Chlorinated N-tert-Butanesulfinyl Ketimines  $(S_S)$ -3a-3p. With the sulfinyl ketimines in hand, the preparation of 2-substituted pyrrolidines via asymmetric reduction of the  $\gamma$ -chloro N-tert-butanesulfinyl ketimines was explored. Reduction of sulfinyl ketimine  $(S_{S})$ -3a with 1.1 equiv of LiBHEt<sub>3</sub> in dry THF at -78 °C for 3 h followed by extractive workup afforded the crude  $\gamma$ -chloro sulfinamide (S<sub>S</sub>, R)-8a in quantitative yield with little or no formation of the ring-closed product, i.e., pyrrolidine  $(S_S, R)$ -4a (Scheme 3). Gratifyingly, further stirring the crude  $\gamma$ -chloro sulfinamide **8a** with a strong base such as LiHMDS in THF at rt for 1 h afforded the desired pyrrolidine  $(S_S, R)$ -4a in 90% overall yield from 3a with a high diastereomeric ratio of 99:1 (Scheme 3). The diastereoselectivity of the reaction was determined on the basis of <sup>1</sup>H NMR analysis of the crude product. The (R)-1-((S)-tertbutylsulfinyl)-2-(4-bromophenyl)pyrrolidine (4a) was obtained as a colorless crystalline solid (mp 120-122 °C). The structure and absolute configuration of  $(S_S, R)$ -4a was confirmed by single crystal X-ray diffraction analysis (see Supporting Information). Further optimization of this (3a to 4a) two-step process to one step was achieved by warming the reaction mixture at -78 to 23 °C followed by stirring for 1 h, yielded pyrrolidine  $(S_S, R)$ -4a in a single step in 96% yield with a high diastereoselectivity of 99:1.

Thrilled with these results, a series of metal hydrides were screened to further elaborate this reduction and test the possibility of stereoselectivity reversal. A series of reducing agents, such as L-Selectride, NaBH4, LiBH4, 9-BBN, NaBH<sub>3</sub>CN, LiAlH<sub>4</sub>, and DIBAL-H, were studied in the reduction of  $\gamma$ -chloro N-tert-butanesulfinyl ketimines 3b in THF for 3 h at -78 °C. Selectivity was monitored after cyclization of crude sulfinamide 8b to the desired crude pyrrolidines 4b and 5b by using 1.5 equiv of LiHMDS. (Table 1). Reduction with L-Selectride provided a similar result as LiBHEt<sub>3</sub> (99:1 dr, Table 1, entry 1). We were gratified to find the reversal of diastereoselectivity with a ratio of 40:60 (4b/5b) when NaBH<sub>4</sub> was used as a reducing agent (Table 1, entry 2). Replacing NaBH<sub>4</sub> with LiBH<sub>4</sub> resulted in a slightly better outcome with a 35:65 dr (Table 1, entry 3). Reduction using a sterically hindered

 TABLE 1.
 Reductive Cyclization of Sulfinyl Ketimine  $(S_S)$ -3b Using Various Metal Hydrides



<sup>*a*</sup>All reactions were performed using 1.5 equiv of reducing agent at -78 °C for 3 h, followed by isolation of crude product and cyclization using LiHMDS, rt, 1 h in dry THF, unless stated otherwise indicated. <sup>*b*</sup>10 equiv of MeOH was used. <sup>c</sup>The diastereoselectivity was determined by <sup>1</sup>H NMR analysis. The "99:1 or 1:99" denotes that signals for only one diastereomer were observed.

toluene

100

1:99

7

DIBAL-H

SCHEME 4. Asymmetric Reductive Cyclization of  $\gamma$ -Chlorinated *N-tert*-Butanesulfinyl Ketimine ( $S_S$ )-3a using DIBAL-H and LiHMDS



reducing agent like 9-borabicyclo[3.3.1]nonane (9-BBN) failed to show any improvement (38:62 dr, Table 1, entry 4). Interestingly, LiAlH<sub>4</sub> showed an improved diastereoselectivity of 18:82 dr, (Table 1, entry 6). To our delight, when DIBAL-H was used, a marked enhancement in diastereoselectivity was observed with a diastereomeric ratio of 4:96 (Table 1, entry 7). The diastereoselectivity was further improved to 1:99 when the reduction was conducted in toluene instead of THF (Table 1, entry 8).

Pleased with these results, we focused our efforts on developing a single-step method to yield **5b** with high diastereoselectivity. Unlike the LiBHEt<sub>3</sub> conditions, pyrrolidine **5b** was not observed during the reduction of sulfinyl ketimine **3a** with DIBAL-H at -78 °C for 3 h followed by warming to rt and stirring for 1-12 h. We reasoned that the low basicity of the corresponding aluminum complex may inhibit the cyclization. With this rationale the addition of LiHMDS to the reaction mixture followed by warming the reaction mixture from -78 to 23 °C led to complete cyclization. Thus, in one pot we were able to synthesize (*S<sub>S</sub>*,*S*)-**5a** in a 90%

TABLE 2. Asymmetric Reductive Cyclization of  $\gamma$ -Chlorinated *N*-tert-Butanesulfinyl Ketimine ( $S_S$ )-3a-3l with LiBHEt<sub>3</sub> and DIBAL-H/ LiHMDS

>/s=0 	D R <mark>← DIBAL-H , –7</mark> LiHMDS, rt, 2 h	8 °C, 3 h I, toluene R <sup>2</sup>		<u>3HEt₃, –78 °C,</u> rt, 1 h, THF	
		LiBHEt <sub>3</sub>		DIBAL-H	
entry	R	product	yield <sup><i>a</i></sup> $(dr)^b$	product	yield <sup><math>a</math></sup> (dr) <sup><math>b</math></sup>
1	$4-BrC_6H_4$	4a	96 (99:1)	5a	90(1:99)
2	C <sub>6</sub> H <sub>5</sub>	4b	94 (99:1)	5b	92 (1:99)
3	4-MeC <sub>6</sub> H <sub>4</sub>	4c	92 (99:1)	5c	93 (1:99)
4	4-MeOC <sub>6</sub> H <sub>4</sub>	4d	90 (99:1)	5d	87 (1:99)
5	$4-tBuC_6H_4$	<b>4</b> e	93 (99:1)	5e	91 (1:99)
6	$4 - HOC_6H_4$	<b>4</b> f	98 (99:1)	5f	94 (1:99)

7 3-MeOC<sub>6</sub>H<sub>4</sub> 92 (99:1) 90 (1:99) 4g 5g 98 (99:1) 5h 93 (1:99) 8 4-ClC<sub>6</sub>H<sub>4</sub> 4h 98 (1:99) 9  $4-FC_6H_4$ 4i 93 (99:1) 5i 5j 95 (1:99) 10 2-thienyl 4j 93 (99:1) C<sub>6</sub>H<sub>11</sub> 4k 94 (99:1) 5ĸ 95 (1:99) 11 12 Me 41 88 (8:92) 51 89 (91:9) <sup>a</sup>Isolated yield of analytically pure products. <sup>b</sup>The diastereoselectivity

"Isolated yield of analytically pure products." The diastereoselectivity was determined by <sup>1</sup>H NMR analysis. The "99:1 or 1:99" denotes that signals for only one diastereomer were observed; dr relative to sulfur.

yield with a high diastereomeric ratio of 1:99 (Scheme 4). The structure and absolute configuration of  $(S_S,S)$ -**5a** was confirmed by comparing the <sup>1</sup>H NMR, <sup>13</sup>C NMR, and specific rotation data with literature data.<sup>19</sup>

Scope of the Reaction. With optimized one-step processes to access either of the two diastereomers of 2-substituted pyrrolidines ( $S_S$ , R)-4 and ( $S_S$ , S)-5 starting from N-sulfinyl ketimines 3, a variety of  $\gamma$ -chlorinated N-tert-butanesulfinyl ketimines ( $S_S$ )-3 were used as substrates to probe the general

#### SCHEME 5. Asymmetric Synthesis of 2-Subtituted Piperidines

applicability (Table 2). In the LiBHEt<sub>3</sub> mediated reductive cyclization of phenyl y-chloro N-tert-butanesulfinyl ketimine 3b, substituents such as OMe, Me, t-Bu, OH, Cl, Br, F, etc. in the para and meta positions of the phenyl ring (3c-3i) were well tolerated, and high diastereoselectivity (99:1 dr) and high yields were obtained in every instance. (Table 2, entries 3-6). Similarly, treatment 3c-3i with DIBAL-H/LiHMDS afforded the corresponding 2-aryl substituted pyrrolidines (5c-5i) in 88-94% yields with high diastereoselectivity (99:1 dr). Furthermore, heteroaryl ketimine 3i, when treated with LiBHEt<sub>3</sub> or DIBAL-H/ LiHMDS, also underwent stereoselective reductive cyclization to afford 4j or 5j with diastereomeric ratio of 99:1 and 1:99 in 93% and 95% yields, respectively (Table 2, entry 10). In addition, these reactions were also found to be tolerant to aliphatic ketimines (Table 2, entries 11 and 12). Treatment of cyclohexyl sulfinyl ketimine 3k with LiBHEt<sub>3</sub> or DIBAL-H/ LiHMDS also afforded the corresponding pyrrolidines 4k or 5k in 94% and 95% yield with diastereomeric ratios of 99:1 and 1:99, respectively (Table 2, entry 10). However, when methyl ketimine 31 was subjected to LiBHEt<sub>3</sub> conditions, the reverse stereoselective product, i.e., (R)-1-((S)-tert-butylsulfinyl)-2-methylpyrrolidine  $(S_S, R-5I)$  was obtained with slightly lower diastereoselectivities (8:92 dr) in 88% yield (Table 2, entry 12). In the same way, treatment of 31 with DIBAL-H/LiHMDS afforded the reverse stereoselective product, i.e., (S)-1-((S)-tert-butylsulfinyl)-2-methyl-pyrrolidine  $(S_{\rm S},S-4I)$  with 89% yield and diastereometric ratio of 91:9 (Table 2, entry 12). Thus, as summarized in Table 2, all reactions took place readily and afforded the corresponding pyrrolidines in good to excellent yields with high diastereoselectivities.

Asymmetric Synthesis of 2-Substituted Piperidines and Azepanes. Extension of this methodology to the asymmetric



# JOC Article

synthesis of 2-substituted piperidines, azepanes, and azocines was investigated. Reduction of  $\delta$ -chlorinated *N*-tert-butanesulfinyl ketimine (3m) with LiBHEt<sub>3</sub> at -78 °C for 3 h followed by increasing the reaction temperature to rt and stirring overnight led to the desired 2-phenyl piperidine 10m with high diastereoselectivity (99:1) and 94% yield (Scheme 5). Likewise, treatment of 3m with DIBAL-H/LiHMDS afforded reversal of diastereofacial selectivity, and 2-phenyl piperidine 11m was obtained with dr of 1:99 in 92% yield (Scheme 5). Excited by these results, we moved on to the preparation of larger ring systems like azepanes (seven-membered) and azocines (eightmembered). Treatment of  $\varepsilon$ -chlorinated *N*-tert-butanesulfinyl ketimine (3n) with LiBHEt<sub>3</sub> at -78 °C for 3 h afforded the  $\varepsilon$ chloro sulfinamide 12n in quantitative yield and high diastereoselectivity (99:1 dr). However, ensuing efforts to cyclize 12n by warming the reaction to rt and stirring for 2 days failed to afford the cyclized azepane ring. Prolonged stirring of 12n with LiBHEt<sub>3</sub> at rt led to the dechlorinated side product 13n (Scheme 5). Similarly, treatment of 3n with DIBAL-H at -78 °C for 3 h also led to complete conversion of **3n** to **14n**, but subsequent treatment with LiHMDS at rt and stirring for 2 days did not result in the cyclized azepane (Scheme 5). A series of other bases (BuLi, NaH, LiHMDS, Et<sub>3</sub>N, and KOH) were investigated in different solvents to promote cyclization of 12n and 14n to the seven-membered ring; however, no cyclization was occurred (see the Supporting Information). We reasoned that the increased strain coupled with high activation energy of the transition state may inhibit the cyclization. Similar results were obtained with  $\zeta$ -chlorinated *N*-tert-butanesulfinyl ketimine( $S_S$ )-30.

SCHEME 6. Reduction of Dechlorinated *N*-tert-Butanesulfinyl Ketimine  $(S_S)$ -3p



**Mechanistic Rationale/Reasoning.** Intrigued by the reversal of diastereofacial selectivity upon changing reducing agents from LiBHEt<sub>3</sub> to DIBAL-H, we pursued the reason for this diastereoselective switch. To exclude the role of the chloro group in the diastereoselectivity of the reducing agents, we synthesized the dechlorinated ketimine **3p** (Scheme 6). Reduction of **3p** with DIBAL-H and LiBHEt<sub>3</sub> using the conditions mentioned earlier resulted in the formation of **15p** and **16p**, respectively, with high diastereoselectivity (Scheme 6), demonstrating that the chloro group does not play a role. We propose that the DIBAL-H reaction proceeds through a closed transition state where the aluminum metal coordinates with the sulfinyl oxygen directing the hydride attack from the *si* face of the imine bond to give the (*S<sub>S</sub>*,*S*) diastereomer (Figure 1, TS 1). Alternatively,



TTS 1 (DIBAL-H)



TTS 2 (LiBHEt<sub>3</sub>)

**FIGURE 1.** Proposed transition states for the reduction of sulfinyl ketimines  $(S_S)$ -3.

poorly coordinating and rapidly reacting LiBHEt<sub>3</sub> was posed to attack the electrophilic carbon atom in a sterically controlled fashion via an open transition state. Hence, delivery of the hydride would occur from the same face as the sulfur lone pair to give the  $(S_S, R)$  diastereomer (Figure 1, TS 2).

#### SCHEME 7. Selective Deprotection of Sulfinyl Group



Deprotection To Generate Single Enantiomers of 2-Subtituted Pyrrolidines. Finally, dissolving 4a in methanol followed by treatment with 4 M HCl for 30 min led to cleavage of the sulfinyl group resulting in the formation of the (R)-2-(4-bromophenyl) pyrrolidine (17a) as a single enantiomer in 98% yield (Scheme 7). The other diastereomer 5a also underwent smooth deprotection to afford (S)-2-(4bromophenyl)pyrrolidine (ent-17a) in 97% yield. The chloro substituted pyrrolidine 4h and 5h were also tested under these conditions and were found to give similar results. In the same way, treatment of 4l or 5l with 4 M HCl (dioxane) in methanol for 30 min afforded the (S)-2-(4-bromophenyl)pyrrolidine (171) or (R)-2-(4-bromophenyl)pyrrolidine (ent-171) in 95% and 92% yields, respectively. The absolute configuration of (S)-17l and (R)-ent-17l was confirmed by comparing the specific rotation data with literature data.<sup>25</sup>

Thus, the sulfinyl group can be cleaved readily under mild acidic conditions to provide the respective amines in excellent yields.

<sup>(25) (</sup>a) Kim, M.-J.; Lim, G-B; Whang, S-Y; Ku, B.-C.; Choi, J.-Y. Bioorg. Med. Chem. Lett. 1996, 6, 71. (b) Kostyanovsky, R. G.; Gella, I. M.; Markov, V. I; Samojlova, Z. E. Tetrahedron 1974, 30, 39.

### SCHEME 8. Asymmetric Reductive Cyclization of Methyl Ketimine 31 and Selective Deprotection of Sulfinyl Group



**Conclusion.** In conclusion, we have developed a highly efficient, versatile one-step process for asymmetric synthesis of either stereoisomer of 2-substituted pyrrolidines from the same starting material with excellent yields and high diastereoselectivety. This method was also applied for the asymmetric synthesis of both diastereomers of 2-substituted piperidines with good yields and excellent diastereoselectivety. This method was found to be effective for a variety of substrates incorporating various aromatic and aliphatic substituents. Extension of this work is currently underway in our laboratory.

#### **Experimental Section**

General Procedure (GP1) for the Synthesis of  $\gamma$ -Chloro *N*-Sulfinyl Ketimine 3. A 500 mL, three-necked, round-bottomed flask was charged with 1-(4-bromophenyl)-4-chlorobutan-1-one 6a (40.0 mmol), THF (100 mL), *tert*-butanesulfinamide 7 (60.0 mmol), and Ti(OEt)<sub>4</sub> (80.0 mmol) under nitrogen atm. The reaction mixture was then heated at reflux at 65 °C for 48 h. After completion, the reaction was allowed to cool to rt. Isopropyl acetate (100 mL) and saturated NaCl solution (100 mL) were then added to this mixture and stirred for 1 h. The solids were removed by filtration, and the filtrate was washed with water (2 × 50 mL). The organic phase was evaporated under vacuum to dryness to obtain the crude product. The crude product was purified by flash column chromatography (silica gel, 10% ethyl acetate in heptanes) to afford the pure  $\gamma$ -chloro *N*-sulfinyl ketimine 3a.

(*S*,*E*)-*N*-(4-Chloro-1-(4-bromophenyl)butylidene)-2-methylpropane-2-sulfinamide (3a). Following the general procedure (GP1), the reaction of 4-chloro-1-(4-bromophenyl)-butan-1-one (6b) (25.5 g, 100.0 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (13.3 g, 110.0 mmol) and Ti(OEt)<sub>4</sub> (34.5 g, 150.0 mmol) gave 30.6 g (84%) of pure *γ*-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) **3a** as white solid, mp = 48–50 °C,  $[\alpha]^{25}_{D} = -24.2 (c 1.10, MeOH)$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.66–7.86 (m, 2 H), 7.56 (d, *J* = 8.51 Hz, 2 H), 3.57–3.70 (m, 2 H), 3.19–3.51 (m, 2 H), 2.01–2.28 (m, 2 H), 1.24–1.42 (m, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 176.8, 136.3, 131.9, 128.9, 126.5, 58.0, 44.5, 31.5, 29.8, 22.7. HRMS (EI) calcd for C<sub>14</sub>H<sub>20</sub>NOSBrCl [M + H] 364.0120, found 364.0138.

(*S*,*E*)-*N*-(4-chloro-1-phenyl)butylidene)--2-methylpropane-2sulfinamide (3b). Following the general procedure (GP1), the reaction of 4-chloro-1-phenyl-butan-1-one (6b) (18.2 g, 100.0 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (13.3 g, 110.0 mmol) and Ti(OEt)<sub>4</sub> (34.5 g, 150.0 mmol) gave 25.9 g (91%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) **3b** as white solid, mp =  $35-36 \, ^{\circ}$ C,  $[\alpha]^{25}_{D} = -20.9$  (*c* 1.10, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.79–7.96 (m, 2 H), 7.33–7.56 (m, 3 H), 3.57–3.72 (m, 2 H), 3.23–3.54 (m, 2 H), 2.07–2.28 (m, 2 H), 1.36 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 178.0, 137.5, 131.7, 128.7, 127.4, 57.9, 44.6, 31.6, 30.0, 22.7. HRMS (EI) calcd for C<sub>14</sub>H<sub>21</sub>NOSI [M + H] 286.1024, found 286.1032.

(*S*,*E*)-*N*-(4-Chloro-1-*p*-tolylbutylidene)-2-methylpropane-2sulfinamide (3c). Following the general procedure (GP1), the reaction of 4-chloro-1-*p*-tolyl-butan-1-one (6c) (25 g, 127.0 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (23.1 g, 190.6 mmol) and Ti(OEt)<sub>4</sub> (57.9 g, 254.2 mmol) gave 34.3 g (90%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) 3c as viscous oil,  $[\alpha]^{25}{}_{\rm D} = -17.5 (c 1.03, MeOH)$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.74–7.83 (m, 2 H), 7.24 (d, *J* = 8.20 Hz, 2 H), 3.59–3.67 (m, 2 H), 3.22–3.49 (m, 2 H), 2.40 (s, 3 H), 2.08–2.25 (m, 2 H), 1.34 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 178.0, 142.4, 134.8, 129.4, 127.5, 57.7, 53.4, 44.7, 31.7, 30.0, 22.7, 21.4. HRMS (EI) calcd for C<sub>15</sub>H<sub>23</sub>NOSC1 [M + H] 300.1189, found 300.1176.

(*S*,*E*)-*N*-(4-Chloro-1-(4-methoxyphenyl)butylidene)-2-methylpropane-2-sulfinamide (3d). Following the general procedure (GP1), the reaction of 4-chloro-1-(4-methoxyphenyl)butan-1one (6d) (25 g, 117.5 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (21.37 g, 176.32 mmol) and Ti(OEt)<sub>4</sub> (57.9 g, 235.1 mmol) gave 31.56 g (85%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) 3d as viscous oil,  $[\alpha]^{25}_{D} = -28.3$  (*c* 1.15, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.83–7.91 (m, 2 H), 6.88–6.97 (m, 2 H), 3.86 (s, 3 H), 3.59–3.68 (m, 2 H), 3.19–3.47 (m, 2 H), 2.07–2.27 (m, 2 H), 1.32 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 178.0, 162.6, 130.0, 129.4, 114.4, 57.5, 55.4, 53.4, 44.8, 31.7, 29.9, 22.6. HRMS (EI) calcd for C<sub>15</sub>H<sub>23</sub>NO<sub>2</sub>SCl [M + H] 316.1138, found 316.1125.

(*S*,*E*)-*N*-(1-(4-*tert*-Butylphenyl)-4-chlorobutylidene)-2-methylpropane-2-sulfinamide (3e). Following the general procedure (GP1), the reaction of 1-(4-tert-butylphenyl)-4-chlorobutan-1one (6e) (10 g, 41.885 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (7.614 g, 62.83 mmol) and Ti(OEt)<sub>4</sub> (19.112 g, 83.77 mmol) gave 13.6 g (90%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) **3e** as viscous oil,  $[\alpha]^{25}{}_{\rm D} = -18.9 (c 1.0, MeOH)$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.76–7.90 (m, 2 H), 7.45 (d, *J* = 7.57 Hz, 2 H), 3.59–3.69 (m, 2 H), 3.21–3.51 (m, 2 H), 2.08–2.27 (m, 2 H), 1.34 (s, 18 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 177.8, 155.3, 134.7, 127.3, 125.6, 57.7, 53.4, 44.7, 34.9, 31.7, 31.1, 28.1, 22.7. HRMS (EI) calcd for C<sub>18</sub>H<sub>29</sub>NOSCI [M + H] 342.1653, found 342.1657.

(*S*,*E*)-*N*-(4-Chloro-1-(4-hydroxyphenyl)butylidene)-2-methylpropane-2-sulfinamide (3f). Following the general procedure (GP1), the reaction of 5-chloro-1-(4-hydroxy-phenyl)butan-1one (6f) (10 g, 50.34 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (9.15 g, 75.51 mmol) and Ti(OEt)<sub>4</sub> (22.969 g, 100.68 mmol) gave 9.87 g (65%) of pure  $\gamma$ -chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) **3f** as a solid, mp = 88–90 °C, [ $\alpha$ ]<sup>25</sup><sub>D</sub> = -52.0 (*c* 1.04, MeOH). <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  ppm 10.26 (s, 1 H), 7.81 (d, J = 7.58 Hz, 2 H), 6.86 (d, J = 8.84 Hz, 2 H), 3.71 (t, J = 6.57 Hz, 2 H), 3.10–3.33 (m, 2 H), 1.88–2.12 (m, 2 H), 1.21 (s, 9 H). <sup>13</sup>C NMR (125 MHz, DMSO- $d_6$ ))  $\delta$  ppm 178.9, 161.2, 129.6, 127.7, 115.4, 56.3, 44.7, 31.5, 29.4 22.0. HRMS (EI) calcd for C<sub>14</sub>H<sub>21</sub>NO<sub>2</sub>SCl [M + H] 302.0982, found 302.1011.

(*S*,*E*)-*N*-(4-Chloro-1-(3-methoxyphenyl)butylidene)-2-methylpropane-2-sulfinamide (3g). Following the general procedure (GP1), the reaction of 5-chloro-1-(3-methoxyphenyl)butan-1one (6g) (5 g, 23.51 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (4.27 g, 35.26 mmol) and Ti(OEt)<sub>4</sub> (10.72 g, 47.02 mmol) gave 6.08 g (82%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) 3g as a viscous liquid,  $[\alpha]^{25}_{\rm D} = -10.4$  (*c* 1.42, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.40–7.49 (m, 2 H), 7.34 (t, *J* = 7.88 Hz, 1 H), 7.03 (d, *J* = 7.25 Hz, 1 H), 3.83 (s, 3 H), 3.60–3.66 (m, 2 H), 3.23–3.48 (m, 2 H), 2.08–2.25 (m, 2 H), 1.33 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 177.7, 159.7, 138.9, 129.6, 119.8, 117.5, 112.6, 57.9, 55.3, 44.6, 31.7, 30.0, 22.7. HRMS (EI) calcd for C<sub>15</sub>H<sub>23</sub>NO<sub>2</sub>SCI [M + H] 316.1133, found 316.1134.

(*S*,*E*)-*N*-(4-Chloro-1-(4-chlorophenyl)butylidene)-2-methylpropane-2-sulfinamide (3h). Following the general procedure (GP1), the reaction of 4-chloro-1-(4-chlorophenyl)butan-1-one (6h) (10 g, 46.06 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (8.374 g, 69.95 mmol) and Ti(OEt)<sub>4</sub> (21.018 g, 92.12 mmol) gave 13.7 g (93%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) 3h as a white color solid, mp = 40-42 °C,  $[\alpha]^{25}_{D} = -26.9 (c 1.12, MeOH)$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.75-7.88 (m, 2 H), 7.41 (d, *J* = 8.51 Hz, 2 H), 3.59-3.69 (m, 2 H), 3.23-3.49 (m, 2 H), 2.04-2.25 (m, 2 H), 1.32 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 176.8, 138.0, 135.9, 129.0, 128.7, 58.0, 44.6, 31.6, 29.8, 22.7. HRMS (EI) calcd for C<sub>14</sub>H<sub>20</sub>NOSCl<sub>2</sub> [M + H] 320.06378, found 320.0638.

(*S*,*E*)-*N*-(4-Chloro-1-(4-fluorophenyl)butylidene)-2-methylpropane-2-sulfinamide (3i). Following the general procedure (GP1), the reaction of 4-chloro-1-(4-fluorophenyl)butan-1-one (6i) (10 g, 49.84 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (9.06 g, 74.76 mmol) and Ti(OEt)<sub>4</sub> (22.74 g, 99.68 mmol) gave 14.2 g (94%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) **3i** as a white color solid, mp = 38–40 °C,  $[\alpha]^{25}_{D}$  = -40.7 (*c* 1.05, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.85–7.96 (m, 2 H), 7.12 (t, *J* = 8.51 Hz, 2 H), 3.60–3.70 (m, 2 H), 3.23–3.49 (m, 2 H), 2.08–2.26 (m, 2 H), 1.35 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 176.8, 165.9, 163.9, 133.7, 129.8, 129.7, 115.8, 115.7, 115.4, 57.8, 44.6, 31.6, 29.9, 22.7. HRMS (EI) calcd for C<sub>14</sub>H<sub>20</sub>NOSCIF [M + H] 304.0938, found 304.0926.

(*S*,*E*)-*N*-(4-Chloro-1-(thiophen-2-yl)butylidene)-2-methylpropane-2-sulfinamide (3j). Following the general procedure (GP1), the reaction of 4-chloro-1-(thiophen-2-yl)butan-1-one (6j) (5 g, 26.5 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (4.817 g, 39.75 mmol) and Ti(OEt)<sub>4</sub> (12.09 g, 53.0 mmol) gave 7.5 g (97%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) **3j** as a viscous liquid,  $[\alpha]^{25}{}_{\rm D} = -90.0 (c 1.06, MeOH)$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.58 (d, *J* = 3.15 Hz, 1 H), 7.50 (d, *J* = 5.04 Hz, 1 H), 7.07–7.12 (m, 1 H), 3.60–3.70 (m, 2 H), 3.33–3.42 (m, 1 H), 3.23 (dd, *J* = 10.72, 5.67 Hz, 1 H), 2.15–2.35 (m, 2 H), 1.30 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 172.3, 144.9, 132.3, 129.6, 128.0, 58.0, 44.6, 32.1, 30.6, 22.5. HRMS (EI) calcd for C<sub>12</sub>H<sub>19</sub>NOS<sub>2</sub>Cl [M + H] 292.0597, found 292.0573.

(*S*,*E*)-*N*-(4-Chloro-1-cyclohexyl-butylidene)-2-methylpropane-2-sulfinamide (3k). Following the general procedure (GP1), the reaction of 4-chloro-1-cyclohexyl-butan-1-one (6k) (9.1 g, 50.0 mmol) with (*S<sub>S</sub>*)-*tert*-butanesulfinamide (9.06 g, 74.76 mmol) and Ti(OEt)<sub>4</sub> (22.74 g, 99.68 mmol) gave 13.2 g (90%) of pure  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) 3k as a viscus oil,  $[\alpha]^{25}_{D} =$ -32.8 (*c* 1.02, MeOH). <sup>1</sup>H NMR (501 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  ppm 3.63-3.76 (m, 2 H), 2.62-2.74 (m, 2 H), 2.20-2.33 (m, 1 H), 2.00-2.11 (m, 2 H), 1.76-1.87 (m, 2 H), 1.53-1.69 (m, 3 H), 1.16-1.36 (m, 5 H), 1.12 (s, 9 H). <sup>13</sup>C NMR (125 MHz, DMSO*d*<sub>6</sub>)  $\delta$  ppm 168.7, 55.9, 48.7, 44.5, 32.7, 27.68, 25.4, 24.4, 21.7. HRMS (EI) calcd for  $C_{14}H_{27}NOSCl\,[M\,+\,H]$  292.8883, found 292.8885.

(*S*,*E*)-*N*-(4-Chloro-1-methyl)-2-methylpropane-2-sulfinamide (3l). Following the general procedure (GP1), the reaction of 4-chloro-1-methyl-butan-1-one (61l) (12.0 g, 100.0 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (13.3 g, 110.0 mmol) and Ti(OEt)<sub>4</sub> (34.5 g, 150.0 mmol) gave 18.8 g (85%) of pure  $\gamma$ -chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) **3l** as a viscous liquid,  $[\alpha]^{25}_{D} = -21.1$ (*c* 1.60, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 3.60 (t, *J* = 6.31 Hz, 2 H), 2.60 (t, *J* = 7.09 Hz, 2 H), 2.35 (s, 3 H), 2.00–2.16 (m, 2 H), 1.24 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 183.8, 56.3, 44.2, 39.9, 27.9, 23.3, 22.1. HRMS (EI) calcd for C<sub>9</sub>H<sub>19</sub>ClNOS [M + H] 224.0876, found 224.0861.

(*S*,*E*)-*N*-(5-Chloro-1-phenylpentylidene)-2-methylpropane-2sulfinamide (3m). Following the general procedure (GP1), the reaction of 5-chloro-1-phenylpentan-1-one (6m) (10 g, 50.84 mmol) with (*S<sub>S</sub>*)-*tert*-butanesulfinamide (9.24 g, 76.26 mmol) and Ti(OEt)<sub>4</sub> (23.2 g, 101.68 mmol) gave 13.72 g (90%) of pure γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3m** as a viscous liquid,  $[\alpha]^{25}_{D} = +23.6 (c 1.02, MeOH)$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.78–7.91 (m, 2 H), 7.39–7.51 (m, 3 H), 3.51–3.61 (m, 2 H), 3.14–3.37 (m, 2 H), 1.78–1.95 (m, 4 H), 1.33 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 179.0 137.7, 131.5, 128.6, 127.3, 57.7, 44.3, 32.3, 31.3, 25.9, 22.7. HRMS (EI) calcd for C<sub>15</sub>H<sub>23</sub>NOSCl [M + H] 300.1183, found 300.1184.

(*S*,*E*)-*N*-(6-Chloro-1-phenylhexylidene)-2-methylpropane-2sulfinamide (3n). Following the general procedure (GP1), the reaction of 6-chloro-1-phenylhexan-1-one (6n) (10 g, 47 mmol) with (*S*<sub>S</sub>)-*tert*-butanesulfinamide (8.6 g, 71.4 mmol) and Ti(OEt)<sub>4</sub> (20.71 g, 94 mmol) gave 13.42 g (90%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) **3n** as a viscous liquid,  $[\alpha]^{25}{}_{\rm D}$  = +12.4 (*c* 1.22, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.83 (br. s., 2 H), 7.40–7.51 (m, 3 H), 3.57 (none, 1 H), 3.51 (t, *J* = 6.46 Hz, 2 H), 3.23–3.34 (m, 1 H), 3.12–3.22 (m, 1 H), 1.77–1.85 (m, 2 H), 1.65–1.74 (m, 2 H), 1.54–1.63 (m, 2 H), 1.35 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 179.5, 137.8, 131.5, 128.6, 127.3, 57.3, 44.7, 32.2, 32.0, 27.9, 27.0, 22.7. HRMS (EI) calcd for C<sub>16</sub>H<sub>25</sub>NOSCI [M + H] 314.1345, found 314.1347.

(*S*,*E*)-*N*-(7-Chloro-1-phenylhexylidene)-2-methylpropane-2sulfinamide (30). Following the general procedure (GP1), the reaction of 7-chloro-1-phenylheptan-1-one (60) (11.5 g, 50.0 mmol) with (*S<sub>S</sub>*)-*tert*-butanesulfinamide (9.0 g, 75.0 mmol) and Ti(OEt)<sub>4</sub> (22.8 g, 100.0 mmol) gave 14.5 g (89%) of pure γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **30** as a viscous liquid,  $[\alpha]^{25}_{D} = +29.0$ (*c* 1.02, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.74–7.92 (m, 2 H), 7.35–7.53 (m, 3 H), 3.51 (t, *J* = 6.78 Hz, 2 H), 3.06–3.36 (m, 2 H), 1.62–1.85 (m, 4 H), 1.40–1.54 (m, 4 H), 1.32 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 179.8, 137.9, 131.4, 128.5, 127.4, 57.5, 44.9, 32.4, 29.0, 28.4, 26.5, 22.7. HRMS (EI) calcd for C<sub>17</sub>H<sub>27</sub>CINOS [M + H] 328.1502, found 328.1504.

(*S*,*E*)-2-Methyl-*N*-(1-phenylbutylidene)propane-2-sulfinamide (3**p**). Following the general procedure (GP1), the reaction of 1phenylpentan-1-one (6**p**) (10 g, 67.47 mmol) with (*S*<sub>S</sub>)-*tert*butanesulfinamide (12.16 g, 101.20 mmol) and Ti(OEt)<sub>4</sub> (30.786 g, 134.94 mmol) gave 15.6 g (92%) of pure γ-chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) 3**p** as a viscous liquid,  $[\alpha]^{25}_{D} = +30.4$ (*c* 1.63, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.78–7.92 (m, 2 H), 7.37–7.52 (m, 3 H), 3.20–3.32 (m, 1 H), 3.07–3.20 (m, 1 H), 1.65–1.78 (m, 2 H), 1.32 (s, 9 H), 1.03 (t, *J* = 7.41 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 180.0, 138.2, 131.4, 128.5, 127.4, 57.3, 34.3, 22.6, 22.2, 14.2. HRMS (EI) calcd for C<sub>14</sub>H<sub>22</sub>NOS [M + H] 252.1422, found 252.1414.

General Procedure (GP2) for the Synthesis of 2-Substituted Pyrrolidines 4. LiBHEt<sub>3</sub> was added to a solution of ketimine 3a (5 mmol) in THF (15 mL) at -78 °C under nitrogen. After stirring for 3 h at -78 °C, the reaction mixture was warmed to rt and stirred for 1 h. On completion, the reaction was quenched

with saturated  $NH_4Cl$  solution (20 mL). The organic layer was then separated, washed with water, and dried under vacuum to give crude product. The crude product was purified by column chromatography (silica gel, ethyl acetate/hexanes) to afford the pure 2-substituted pyrrolidines **4**.

General Procedure (GP3) for the Synthesis of 2-Substituted Pyrrolidines 5. To a solution of ketimine 3a (5 mmol) in toluene (15 mL) at -78 °C was added DIBAL-H under nitrogen. After stirring for 3 h at -78 °C, the reaction mixture was warmed to rt followed by addition of LiHMDS (7.5 mmol) and stirred for 1 h. On completion, the reaction was quenched with saturated K<sup>+</sup>Na<sup>+</sup> tartarate solution (20 mL). The organic layer was then separated, washed with water, and dried under vacuum to give crude product. The crude product was purified by column chromatography (silica gel, ethyl acetate/hexanes) to afford the pure 2-substituted pyrrolidines 5.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-bromophenyl)pyrrolidine (4a). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3a** (1.82 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine **4a** (1.58 g, 96%) as white solid, mp = 120-122 °C, [ $\alpha$ ]<sup>25</sup><sub>D</sub> = +152.3 (*c* 1.13, CHCl<sub>3</sub>). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.44 (d, *J* = 8.51 Hz, 2 H), 7.17 (d, *J* = 8.51 Hz, 2 H), 4.59 (t, *J* = 7.25 Hz, 1 H), 3.83-3.96 (m, 1 H), 2.89-3.05 (m, 1 H), 2.17-2.30 (m, 1 H), 1.68-2.02 (m, 3 H), 1.10 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 142.3, 131.4, 128.9, 121.0, 68.7, 57.2, 42.1, 35.9, 26.3, 23.8. HRMS (EI) calcd for C<sub>14</sub>H<sub>21</sub>BrNOS [M + H] 330.0522, found 330.0527.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-bromophenyl)pyrrolidine (5a). Following the general procedure (GP3), the reaction of γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3a** (3.65 g, 10.0 mmol) with DIBAL-H (12.0 mL, 12.0 mmol, 1.0 M in toluene) and followed by LiHMDS (15.0 mL, 15.5 mmol, 1.0 mL in THF) afforded pyrrolidine **5a** (2.91 g, 90%) as white solid, mp = 100–112 °C,  $[\alpha]^{25}_{D} = -164.3$  (*c* 1.13, CHCl<sub>3</sub>). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.38–7.49 (m, 2 H), 7.14 (d, *J* = 8.51 Hz, 2 H), 5.02 (dd, *J* = 8.20, 2.84 Hz, 1 H), 3.49–3.69 (m, 2 H), 2.16 (dd, *J* = 11.98, 9.14 Hz, 1 H), 1.64–1.96 (m, 3 H), 1.05 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 143.7, 131.4, 128.2, 120.3, 57.4, 56.9, 54.8, 36.4, 24.1, 23.0. HRMS (EI) calcd for C<sub>14</sub>H<sub>21</sub>BrNOS [M + H] 330.0527, found 330.0539.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-phenyl-pyrrolidine (4b). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3b** (1.42 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine **4b** (1.17 g, 94%) as a viscous liquid,  $[\alpha]^{25}{}_{\rm D} = +121.6$  (*c* 1.05, CHCl<sub>3</sub>). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.14–7.40 (m, 5 H), 4.64 (t, *J* = 7.25 Hz, 1 H), 3.83–3.99 (m, 1 H), 2.91–3.04 (m, 1 H), 2.19–2.34 (m, 1 H), 1.71–2.01 (m, 3 H), 1.10 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 143.3, 128.2, 127.2, 69.3, 57.2, 42.1, 35.9, 26.3, 23.8. HRMS (EI) calcd for C<sub>14</sub>H<sub>22</sub>NOS [M + H] 252.1439, found 252.1422.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-phenyl-pyrrolidine (5b). Following the general procedure (GP3), the reaction of γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3b** (1.42 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded pyrrolidine **5b** (1.15 g, 92%) as white solid, mp = 80–81 °C,  $[\alpha]^{25}_{D} = -140.0$  (*c* 1.07, CHCl<sub>3</sub>). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.16–7.34 (m, 5 H), 5.07 (dd, *J* = 8.04, 2.68 Hz, 1 H), 3.61–3.71 (m, 1 H), 3.52–3.60 (m, 1 H), 2.16 (dd, *J* = 11.35, 8.51 Hz, 1 H), 1.71–1.92 (m, 3 H), 1.05 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 143.1, 126.8, 125.0, 55.9, 55.9, 53.3, 35.1, 22.6, 21.5. HRMS (EI) calcd for C<sub>14</sub>H<sub>22</sub>NOS [M + H] 252.1402, found 252.1413.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-methylphenyl)pyrrolidine (4c). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3c** (1.49 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine **4c** (1.21 g, 92%) as a white solid, mp = 62–64 °C, [ $\alpha$ ]<sup>25</sup><sub>D</sub> = +144.6 (*c* 1.03, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.17 (d, *J* = 8.2 Hz, 2 H), 7.11 (d, *J* = 8.2 Hz, 2 H), 4.60 (t, *J* = 7.41 Hz, 1 H), 3.83–3.92 (m, 1 H), 2.92–3.01 (m, 1 H), 2.32 (s, 3 H), 2.15–2.25 (m, 1 H), 1.93–2.01 (m, 1 H), 1.72–1.90 (m, 2 H), 1.10 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 140.2, 136.7, 128.9, 127.1, 69.0, 57.1, 42.0, 35.9, 26.3, 23.8, 21.0. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>NOS [M + H] 266.1573, found 266.1574.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-mehtylphenyl)pyrrolidine (5c). Following the general procedure (GP3), the reaction of γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3b** (1.49 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded pyrrolidine **5c** (1.39 g, 93%) as white solid, mp = 96– 98 °C,  $[\alpha]^{20}_{D} = -159.0$  (*c* 0.8, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.09–7.17 (m, 4 H), 5.02 (dd, *J* = 8.04, 2.68 Hz, 1 H), 3.62–3.70 (m, 1 H), 3.50–3.57 (m, 1 H), 2.32 (s, 3 H), 2.08–2.18 (m, 1 H), 1.77–1.90 (m, 2 H), 1.70–1.78 (m, 1 H), 1.06 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 141.5, 136.0, 129.0, 126.4, 57.5, 57.4, 54.5, 36.6, 24.1, 23.1, 23.0. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>NOS [M + H] 266.1579, found 266.1569.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-methoxyphenyl)pyrrolidine (4d). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) 3d (1.57 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine 4d (1.26 g, 90%) as a white solid, mp =  $61-63 \,^{\circ}\text{C}$ ,  $[\alpha]^{25}_{\text{D}} = +123.2 (c \, 1.0, \text{MeOH})$ . <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.18–7.23 (m, 2 H), 6.82–6.87 (m, 2 H), 4.52–4.61 (m, 1 H), 3.83–3.90 (m, 1 H), 3.78 (s, 3 H), 2.91–3.00 (m, 1 H), 2.14–2.24 (m, 1 H), 1.92–2.02 (m, 1 H), 1.70–1.90 (m, 2 H), 1.09 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ ppm 158.7, 135.0, 128.3, 113.6, 68.6, 57.0, 55.1, 41.9, 35.9, 26.3, 23.8. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>NO<sub>2</sub>S [M + H] 282.1528, found 282.1527.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-methoxyphenyl)pyrrolidine (5d). Following the general procedure (GP3), the reaction of γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) 3d (1.57 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded pyrrolidine 5d (1.22 g, 87%) as white solid, mp = 85–87 °C,  $[\alpha]^{25}_{D} = -140.8$  (*c* 1.09, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.16 (d, *J* = 8.83 Hz, 2 H), 6.83–6.87 (m, 2 H), 4.99 (dd, *J* = 7.88, 2.84 Hz, 1 H), 3.79 (s, 3 H), 3.62–3.70 (m, 1 H), 3.47–3.55 (m, 1 H), 2.07–2.17 (m, 1 H), 1.78–1.91 (m, 2 H), 1.69–1.76 (m, 1 H), 1.06 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 158.2, 136.6, 127.6, 113.7, 57.4, 55.1, 54.2, 36.6, 24.1, 23.1. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>NO<sub>2</sub>S [M + H] 282.1528, found 282.1532.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-*tert*-butylphenyl)pyrrolidine (4e). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3e** (1.70 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine **4e** (1.42 g, 93%) as a white solid, mp = 45–50 °C,  $[\alpha]_{D}^{25}$  = 110.5 (*c* 1.0, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ ppm 7.33 (d, *J* = 8.34 Hz, 2 H), 7.21 (d, *J* = 8.34 Hz, 2 H), 4.64 (t, *J* = 6.95 Hz, 1 H), 3.85–3.92 (m, 1 H), 2.93–3.01 (m, 1 H), 2.17–2.25 (m, 1 H), 1.91–2.00 (m, 1 H), 1.74–1.91 (m, 2 H), 1.31 (s, 9 H), 1.11 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 150.0, 140.1, 126.7, 125.1, 57.2, 42.0, 35.8, 34.4, 31.5, 31.4, 26.2, 23.9. HRMS (EI) calcd for C<sub>18</sub>H<sub>30</sub>NOS [M + H]308.2043, found 308.2046.

(S)-1-((S)-2-Methyl-propane-2-sulfinyl)-2-(4-tert-butylphenyl)pyrrolidine (5e). Following the general procedure (GP3), the reaction of  $\gamma$ -chloro N-sulfinyl ketimine (S<sub>S</sub>) **3e** (1.70 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded pyrrolidine **5**e(1.39 g, 91%) as white solid, mp =  $55-60 \, ^{\circ}$ C,  $[\alpha]^{25}_{D} = -141.0 \, (c \, 1.12, \text{ MeOH}). \, ^{1}$ H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.31 (d,  $J = 8.20 \, \text{Hz}, 2 \, \text{H}), 7.16$  (d,  $J = 8.20 \, \text{Hz}, 2 \, \text{H}), 5.02 \, (\text{dd}, J = 8.04, 2.36 \, \text{Hz}, 1 \, \text{H}), 3.63-3.70 \, (m, 1 \, \text{H}), 3.48-3.54 \, (m, 1 \, \text{H}), 2.09-2.16 \, (m, 1 \, \text{H}), 1.74-1.88 \, (m, 3 \, \text{H}), 1.31 \, (s, 9 \, \text{H}), 1.07 \, (s, 9 \, \text{H}). \, ^{13}$ C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 149.3, 141.2, 126.1, 125.1, 57.8, 57.4, 54.1, 36.4, 34.4, 31.3, 24.1, 23.1. HRMS (EI) calcd for C<sub>18</sub>H<sub>30</sub>NOS [M + H] 308.2048, found 308.2043.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-hydroxylphenyl)pyrrolidine (4f). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3f** (1.50 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine **4f** (1.30 g, 98%) as a white solid, mp = 150 °C,  $[\alpha]^{25}_{D} = +137.4 (c \, 0.93, \text{MeOH})$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$ ppm 7.13 (d, *J* = 8.51 Hz, 2 H), 6.82 (d, *J* = 8.51 Hz, 2 H), 6.50 (br. s., 1 H), 4.53–4.56 (m, 1 H), 3.84–3.89 (m, 1 H), 2.94–3.01 (m, 1 H), 2.18–2.23 (m, 1 H), 1.95–2.01 (m, 1 H), 1.74–1.87 (m, 2 H), 1.12 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 155.6, 134.4, 128.5, 115.2, 68.7, 57.2, 42.2, 35.7, 26.3, 23.8. HRMS (EI) calcd for C<sub>14</sub>H<sub>22</sub>NO<sub>2</sub>S [M + H] 268.1371, found 268.1364.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-hydroxyphenyl)pyrrolidine (5f). Following the general procedure (GP3), the reaction of γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3f** (1.50 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded pyrrolidine **5f** (1.25 g, 94%) as white solid, mp = 185 °C,  $[\alpha]^{2^5}_{D} = -124.4$  (*c* 1.02, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 8.07 (s, 1 H), 7.08 (d, *J* = 8.51 Hz, 2 H), 6.83 (d, *J* = 8.83 Hz, 2 H), 4.87 (dd, *J* = 7.57, 3.15 Hz, 1 H), 3.69–3.76 (m, 1 H), 3.40–3.47 (m, 1 H), 2.13 (dd, *J* = 11.98, 7.88 Hz, 1 H), 1.81–1.92 (m, 2 H), 1.73–1.81 (m, 1 H), 1.13 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 155.8, 134.6, 127.8, 115.5, 60.0, 57.8, 51.9, 36.2, 24.0, 23.4. HRMS (EI) calcd for C<sub>14</sub>H<sub>22</sub>NO<sub>2</sub>S [M + H] 268.1371, found 268.1365.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(3-methoxyphenyl)pyrrolidine (4g). Following the general procedure (GP2), the reaction of γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) 3g (1.57 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine 4g (1.28 g, 92%) as a white solid, mp = 45-50 °C,  $[\alpha]^{25}_{D}$  = +152.8 (*c* 1.12, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>) δ ppm 7.23 (t, *J* = 7.88 Hz, 1 H), 6.82–6.91 (m, 2 H), 6.75–6.81 (m, 1 H), 4.63 (t, *J* = 7.09 Hz, 1 H), 3.86–3.92 (m, 1 H), 3.80 (s, 3 H), 2.95–3.00 (m, 1 H), 2.22–2.27 (m, 1 H), 1.94–2.00 (m, 1 H), 1.77–1.89 (m, 2 H), 1.12 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 159.2, 145.0, 129.3, 119.5, 112.9, 112.4, 69.2, 57.2, 55.1, 42.1, 35.8, 26.2, 23.8. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>NO<sub>2</sub>S [M + H] 282.1528, found 282.1519.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(3-methoxyphenyl)pyrrolidine (5g). Following the general procedure (GP3), the reaction of γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) 3g (1.57 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded pyrrolidine 5g (1.26 g, 90%) as a viscous liquid,  $[\alpha]^{25}_{D} =$ -131.0 (*c* 1.21, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.22 (t, *J* = 7.88 Hz, 1 H), 6.80–6.86 (m, 2 H), 6.75 (dd, *J* = 8.20, 2.52 Hz, 1 H), 5.03–5.05 (m, 1 H), 3.80 (s, 3 H), 3.61–3.68 (m, 1 H), 3.53–3.58 (m, 1 H), 2.11–2.19 (m, 1 H), 1.72–1.92 (m, 3 H), 1.07 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 159.6, 146.4, 129.4, 118.9, 112.4, 111.6, 57.4, 55.1, 54.9, 36.5, 24.2, 23.0. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>NO<sub>2</sub>S [M + H] 282.1528, found 282.1516.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-chlorophenyl)pyrrolidine (4h). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) 3h (1.59 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine 4h (1.39 g, 98%) as a white solid, mp = 75-77 °C, [ $\alpha$ ]<sup>25</sup><sub>D</sub> = +111.9 (*c* 1.09, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.21 (dd, 4 H), 4.55 (t, 1 H), 3.79–3.87 (m, 1 H), 2.87–2.96 (m, 1 H), 2.14–2.23 (m, 1 H), 1.63–1.97 (m, 3 H), 1.05 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 141.8, 132.9, 128.6, 128.4, 68.6, 57.2, 42.1, 36.0, 26.3, 23.8. HRMS (EI) calcd for C<sub>14</sub>H<sub>21</sub>NOSC1 [M + H] 286.1032, found 286.1028.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-chlorophenyl)pyrrolidine (5h). Following the general procedure (GP3), the reaction of γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) 3h (1.59 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded pyrrolidine 5h (1.32 g, 93%) as white solid, mp = 95–102 °C,  $[\alpha]^{25}_{\rm D} = -145.6$  (*c* 0.75, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 7.26–7.31 (m, 2 H), 7.16–7.21 (m, 2 H), 5.04 (dd, *J* = 7.96, 2.65 Hz, 1 H), 3.50–3.69 (m, 1 H), 2.07–2.23 (m, 1 H), 1.65–1.94 (m, 3 H), 1.05 (s, 9 H), 1.05 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 143.2, 132.2, 128.5, 127.9, 57.5, 56.9, 54.9, 36.5, 24.1, 23.0. HRMS (EI) calcd for C<sub>14</sub>H<sub>21</sub>NOSCI [M + H] 286.1032, found 286.1034.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-fluorophenyl)pyrrolidine (4i). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3i** (1.51 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine **4i** (1.25 g, 93%) as a white solid,  $[\alpha]^{25}_{D} = +127.4$ (*c* 1.18, MeOH). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.21–7.30 (m, 2 H), 6.95–7.04 (m, 2 H), 4.58–4.64 (m, 1 H), 3.82–3.93 (m, 1 H), 2.92–3.01 (m, 1 H), 2.20–2.29 (m, 1 H), 1.93–2.01 (m, 1 H), 1.70–1.91 (m, 2 H), 1.09 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ ppm 163.2, 160.8, 138.9, 128.8, 128.7, 115.2, 115.0, 68.5, 57.2, 42.0, 36.0, 26.3, 23.8. HRMS (EI) calcd for C<sub>14</sub>H<sub>21</sub>NOSF [M + H] 270.1322, found 270.1321.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-(4-chlorophenyl)pyrrolidine (5i). Following the general procedure (GP3), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3i** (1.51 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded pyrrolidine **5i** (1.31 g, 98%) as white solid, mp = 80 °C, [ $\alpha$ ]<sup>25</sup><sub>D</sub> = -146.5 (*c* 1.0, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.19–7.24 (m, 2 H), 6.97–7.02 (m, 2 H), 5.04 (dd, *J* = 7.88, 2.84 Hz, 1 H), 3.62–3.69 (m, 1 H), 3.51–3.56 (m, 1 H), 2.12–2.19 (m, 1 H), 1.76–1.92 (m, 2 H), 1.68–1.76 (m, 1 H), 1.05 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 162.5, 160.5, 140.3, 128.0, 128.0, 115.2, 115.0, 57.4, 57.0, 54.5, 36.5, 24.1, 23.0. HRMS (EI) calcd for C<sub>14</sub>H<sub>21</sub>NOSF [M + H] 270.1322, found 270.1320.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-thiophenyl-pyrrolidine (4j). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) 3j (1.45 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine 4j (1.19 g, 93%) as a viscous liquid,  $[\alpha]^{25}_{D} = +98.5$  (*c* 1.21, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.19 (dd, *J* = 4.26, 1.73 Hz, 1 H), 6.90-6.96 (m, 2 H), 4.94 (t, *J* = 6.46 Hz, 1 H), 3.78-3.86 (m, 1 H), 2.91-2.98 (m, 1 H), 2.22-2.30 (m, 1 H), 1.85-2.03 (m, 3 H), 1.14 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 147.9, 126.6, 124.4, 65.1, 57.5, 41.4, 35.8, 26.7, 23.7. HRMS (EI) calcd for C<sub>12</sub>H<sub>20</sub>NOS<sub>2</sub> [M + H] 258.0986, found 258.0979.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2thiophenyl-pyrrolidine (5j). Following the general procedure (GP3), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3j** (1.45 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded pyrrolidine **5j** (1.22 g, 95%) as white solid, mp = 125–130 °C, [ $\alpha$ ]<sup>25</sup><sub>D</sub> = -130.2 (*c* 0.98, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$ ppm 7.15 (d, *J* = 5.04 Hz, 1 H), 6.91–6.95 (m, 1 H), 6.87 (d, *J* = 3.15 Hz, 1 H), 5.24–5.28 (m, 1 H), 3.60–3.66 (m, 1 H), 3.43–3.49 (m, 1 H), 2.07–2.15 (m, 1 H), 1.87–1.96 (m, 3 H), 1.12 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 148.9, 126.7, 123.8, 123.6, 57.6, 54.1, 53.9, 36.7, 24.2, 22.9. HRMS (EI) calcd for C<sub>12</sub>H<sub>20</sub>NOS<sub>2</sub> [M + H] 258.0981, found 258.0979. (*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-cyclohexyl-pyrrolidine (4k). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3k** (1.44 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine **4k** (1.20 g, 94%) as a viscous liquid,  $[\alpha]^{25}_{\rm D} = +106.0$  (*c* 0.75, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 3.68–3.79 (m, 1 H), 3.45–3.52 (m, 1 H), 2.59–2.69 (m, 1 H), 1.73–1.83 (m, 4 H), 1.65–1.72 (m, 4 H), 1.54–1.63 (m, 1 H), 1.40–1.51 (m, 1 H), 1.21 (s, 9 H), 1.07–1.18 (m, 3 H), 0.89–1.05 (m, 2 H), <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 70.7, 57.7, 42.6, 42.3, 30.4, 27.2, 26.8, 26.7, 26.6, 26.5, 26.2, 24.0. HRMS (EI) calcd for C<sub>14</sub>H<sub>28</sub>NOS [M + H] 258.1892, found 258.1890.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-cyclohexyl-pyrrolidine (5k). Following the general procedure (GP3), the reaction of γ-chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3k** (1.45 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 M in THF) afforded pyrrolidine **5k** (1.22 g, 95%) as a viscous liquid,  $[\alpha]^{25}{}_{D} = -40.9 (c \ 1.05, CHCl_3)$ . <sup>1</sup>H NMR (501 MHz, CDCl\_3) δ ppm 3.53–3.63 (m, 1 H), 3.30–3.39 (m, 1 H), 3.14–3.23 (m, 1 H), 1.60–1.83 (m, 10 H), 1.23–1.32 (m, 2 H), 1.20 (s, 9 H), 1.05–1.17 (m, 1 H), 0.89–1.06 (m, 2 H). <sup>13</sup>C NMR (125 MHz, CDCl\_3) δ 62.7, 57.5, 50.0, 41.5, 30.7, 27.4, 27.2, 26.6, 26.5, 26.3, 25.2, 23.4. HRMS (EI) calcd for C<sub>14</sub>H<sub>28</sub>NOS [M + H] 258.1892, found 258.1858.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-methyl-pyrrolidine (4l). Following the general procedure (GP2), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S*<sub>S</sub>) **3l** (1.11 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded pyrrolidine **4l** (0.83 g, 88%) as a viscous liquid,  $[\alpha]^{25}_{D} = +32.5 (c \, 0.89,$ MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 3.77–3.84 (m, 1 H), 3.49–3.57 (m, 1 H), 3.04–3.14 (m, 1 H), 1.77–1.95 (m, 3 H), 1.47–1.54 (m, 1 H), 1.22 (d, *J* = 6.62 Hz, 3 H), 1.19 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 60.7, 57.2, 54.7, 47.1, 41.3, 33.5, 24.0, 23.5, 20.4. HRMS (EI) calcd for C<sub>9</sub>H<sub>20</sub>NOS [M + H] 190.1258, found 190.1266.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-methyl-pyrrolidine (5I). Following the general procedure (GP3), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3I** (1.11 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 M in THF) afforded pyrrolidine **5I** (0.85 g, 89%) as a viscous liquid,  $[\alpha]^{25}_{D} = +83.6 (c \, 1.38, CHCl_3)$ . <sup>1</sup>H NMR (501 MHz, CDCl\_3)  $\delta$  ppm 3.69–3.75 (m, 1 H), 2.73–2.80 (m, 1 H), 1.96–2.04 (m, 1 H), 1.82–1.91 (m, 1 H), 1.67–1.78 (m, 1 H), 1.34–1.45 (m, 1 H), 1.18 (s, 9 H), 1.17 (d, *J* = 5.99 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, CDCl\_3)  $\delta$  ppm 60.6, 56.6, 41.2, 33.7, 25.9, 23.7, 22.0. HRMS (EI) calcd for C<sub>9</sub>H<sub>20</sub>NOS [M + H] 190.1258, found 190.1260.

(*R*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-phenyl-piperidine (10m). Following the general procedure (GP2), the reaction of  $\gamma$ chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3m** (1.49 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded piperidine 10m (1.24 g, 94%) as a white solid, mp = 45–50 °C,  $[\alpha]^{25}_{D} =$ -116.9 (*c* 1.16, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.43 (d, *J* = 8.20 Hz, 2 H), 7.36 (t, *J* = 7.72 Hz, 2 H), 7.20–7.27 (m, 1 H), 4.68 (t, *J* = 4.10 Hz, 1 H), 3.29 (dd, *J* = 8.04, 3.31 Hz, 2 H), 2.16–2.23 (m, 1 H), 2.00–2.09 (m, 1 H), 1.56–1.70 (m, 4 H), 1.42–1.52 (m, 1 H), 1.15 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ ppm 140.2, 128.5, 127.4, 126.6, 58.7, 31.2, 25.6, 23.0, 20.4. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>NOS [M + H] 266.1579, found 266.1563.

(*S*)-1-((*S*)-2-Methyl-propane-2-sulfinyl)-2-phenyl-piperidine (11m). Following the general procedure (GP3), the reaction of  $\gamma$ -chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3m** (1.49 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded piperidine **11m** (1.21 g, 92%) as white solid, mp = 50–55 °C, [ $\alpha$ ]<sup>25</sup><sub>D</sub> = -108.0 (*c* 1.04, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.22–7.36 (m, 5 H), 4.14 (dd, *J* = 8.51, 4.10 Hz, 1 H), 3.31–3.36 (m, 1 H), 2.93–3.01 (m, 1 H), 1.89–1.97 (m, 2 H), 1.73–1.84 (m, 2 H), 1.57–1.66 (m, 1 H), 1.43–1.55 (m, 1 H), 1.13 (s, 9 H).  $^{13}$ C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 141.8, 128.4, 128.2, 127.3, 65.4, 58.1, 43.8, 34.4, 25.5, 24.1, 23.2. HRMS (EI) calcd for C<sub>15</sub>H<sub>24</sub>NOS [M + H] 266.1579, found 266.1550.

(*S*)-2-Methyl-propane-2-sulfinic Acid [(*R*)-6-Chlro-1-phenylhexyl]amide (12n). Following the general procedure (GP2), the reaction of chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3m** (1.56 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded amide **12n** (1.48 g, 94%) as a viscous liquid. <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.24–7.35 (m, 5 H), 4.32–4.38 (m, 1 H), 3.46 (t, *J* = 6.62 Hz, 2 H), 3.40 (d, *J* = 2.84 Hz, 1 H), 1.75–1.88 (m, 2 H), 1.66–1.75 (m, 2 H), 1.37–1.47 (m, 2 H), 1.27–1.37 (m, 1 H), 1.19–1.24 (m, 1 H), 1.17 (s, 9 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 141.9, 128.4, 127.5, 59.2, 55.4, 44.8, 38.5, 32.2, 26.5, 25.2, 22.5. HRMS (EI) calcd for C<sub>16</sub>H<sub>27</sub>NOSCI [M + H] 316.1502, found 316.1499.

(*S*)-2-Methyl-propane-2-sulfinic Acid [(*S*)-6-Chlro-1-phenylhexyl]amide (14n). Following the general procedure (GP3), the reaction of chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3m** (1.56 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded amide **14n** (1.20 g, 93%) as a viscous liquid. <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.25–7.37 (m, 5 H), 4.31–4.35 (m, 1 H), 3.46 (t, *J* = 6.62 Hz, 2 H), 3.40 (d, *J* = 3.47 Hz, 1 H), 1.98–2.07 (m, 1 H), 1.66–1.78 (m, 3 H), 1.35–1.47 (m, 2 H), 1.25–1.32 (m, 1 H), 1.23 (s, 9 H), 1.09–1.19 (m, 1 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 142.4, 128.7, 127.8, 127.1, 58.9, 55.6, 44.8, 36.3, 32.3, 26.6, 24.9, 22.6. HRMS (EI) calcd for C<sub>16</sub>H<sub>27</sub>NOSCI [M + H] 316.1502, found 316.1498.

(*S*)-2-Methyl-propane-2-sulfinic Acid [(*R*)-1-Phenyl-butyl]amide (15p). Following the general procedure (GP2), the reaction of chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3p** (1.26 g, 5.0 mmol) with LiBHEt<sub>3</sub> (6.0 mL, 6.0 mmol, 1.0 M in THF) afforded amide **15p** (1.20 g, 95%) as a viscous liquid,  $[\alpha]^{25}{}_{D} = +89.3 (c \, 1.05, MeOH)$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.31–7.35 (m, 2 H), 7.26–7.30 (m, 3 H), 4.35–4.40 (m, 1 H), 3.36 (br. s., 1 H), 1.72–1.83 (m, 2 H), 1.24–1.36 (m, 1 H), 1.19 (s, 9 H), 0.89 (t, *J* = 7.25 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 142.1, 128.3, 127.6, 127.5, 59.2, 55.4, 40.9, 22.5, 19.2, 13.8. HRMS (EI) calcd for C<sub>14</sub>H<sub>24</sub>NOS [M + H] 254.1579, found 254.1569.

(*S*)-2-Methyl-propane-2-sulfinic Acid [(*S*)-1-Phenyl-butyl]amide (16p). Following the general procedure (GP3), the reaction of chloro *N*-sulfinyl ketimine (*S<sub>S</sub>*) **3p** (1.26 g, 5.0 mmol) with DIBAL-H (6.0 mL, 6.0 mmol, 1.0 M in toluene) and followed by LiHMDS (7.5 mL, 7.5 mmol, 1.0 mL in THF) afforded amide **16p** (1.18 g, 93%) as a viscous liquid,  $[\alpha]^{25}_{D} = +20.2$  (*c* 1.02, MeOH). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.24–7.35 (m, 5 H), 4.31–4.37 (m, 1 H), 3.43 (d, J = 3.47 Hz, 1 H), 1.94–2.04 (m, 1 H), 1.67–1.75 (m, 1 H), 1.21 (s, 9 H), 1.10–1.20 (m, 1 H), 0.88 (t, J = 7.41 Hz, 3 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 142.6, 128.6,127.7, 127.1, 58.9, 55.6, 38.8, 22.6, 18.9, 13.8. HRMS (EI) calcd for C<sub>14</sub>H<sub>24</sub>NOS [M + H] 254.1579, found 254.1574.

General Procedure (GP4) for Deprotection of the *tert*-Butanesulfinyl Group from 4 and 5. To a solution of 4 or 5 (2 mmol) in MeOH (10 mL) was added 4 M HCl solution (in dioxane, 2 mL). After the mixture was stirred at room temperature for 30 min, the mixture was concentrated to dryness and carefully dissolved in water (20 mL). The aqueous layer was washed with ethyl acetate (2 × 20 mL) and neutralized with 6 N NaOH solution to pH ~13. Then, the resulting aqueous solution was extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine and then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The organic layer was concentrated to dryness to obtained pure 2-substituted pyrrolidins 17 or *ent*-17.

(*R*)-2-(4-Bromophenyl)-pyrrolidine (17a). Following the general procedure (GP4), the reaction of 4a (658 mg, 2.0 mmol) with 4 M HCl solution (in dioxane, 2 mL) gives the (*R*)-2-(4-bromophenyl)-pyrrolidine 17a (440 mg, 97%) as viscous oil,

 $\begin{bmatrix} \alpha \end{bmatrix}_{D}^{25} = +52.1 \ (c \ 1.01, CH_2Cl_2). \ ^{1}H \ NMR \ (501 \ MHz, CDCl_3) \ \delta \\ ppm \ 7.40 \ (d, J = 8.51 \ Hz, 2 \ H), \ 7.22 \ (d, J = 8.20 \ Hz, 2 \ H), \ 4.05 \\ (t, J = 7.72 \ Hz, 1 \ H), \ 3.10 - 3.24 \ (m, 1 \ H), \ 2.92 - 3.04 \ (m, 1 \ H), \ 2.08 - 2.23 \ (m, 1 \ H), \ 1.72 - 2.01 \ (m, 3 \ H), \ 1.43 - 1.67 \ (m, 1 \ H). \ ^{13}C \\ NMR \ (125 \ MHz, CDCl_3) \ \delta \ 144.1, \ 131.2, \ 128.2, \ 120.2, \ 61.8, \ 46.9, \ 34.4, \ 25.5. \ HRMS \ (EI) \ calcd \ for \ C_{10}H_{13}BrN \ [M + H] \ 226.0231, \ found \ 226.0229.$ 

(*S*)-2-(4-Bromophenyl)-pyrrolidine (*ent*-17a). Following the general procedure (GP4), the reaction of **5a** (658 mg, 2.0 mmol) with 4 M HCl solution (in dioxane, 2 mL) gives the (*S*)-2-(4-bromophenyl) pyrrolidine *ent*-17a (442 mg, 98%) as viscous oil,  $[\alpha]^{25}_{D} = -51.9 (c 1.27, CH_2Cl_2)$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.41 (d, *J* = 8.20 Hz, 2 H), 7.22 (d, *J* = 8.20 Hz, 2 H), 4.05 (t, *J* = 7.57 Hz, 1 H), 3.11–3.21 (m, 1 H), 2.91–3.05 (m, 1 H), 2.08–2.27 (m, 2 H), 1.69–1.98 (m, 2 H), 1.43–1.67 (m, 1 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  144.0, 131.3, 126.2, 120.3, 61.8, 46.9, 34.4, 25.5. HRMS (EI) calcd for C<sub>10</sub>H<sub>13</sub>BrN [M + H] 226.0226, found 226.0228.

(*R*)-2-(4-Chlorophenyl)-pyrrolidine (17h). Following the general procedure (GP4), the reaction of 4h (570 mg, 2.0 mmol) with 4 M HCl solution (in dioxane, 2 mL) gives the (*R*)-2-(4-chlorophenyl)-pyrrolidine 17h (347 mg, 96%) as viscous oil,  $[\alpha]^{25}_{D} = +41.1 (c 1.05, CH_2Cl_2)$ . <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 7.21–7.38 (m, 4 H), 4.09 (t, J = 7.72 Hz, 1 H), 3.09–3.27 (m, 1 H), 2.90–3.07 (m, 1 H), 2.08–2.27 (m, 1 H), 1.70–2.03 (m, 3 H), 1.49–1.71 (m, 1 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 143.5, 132.2, 128.9, 127.8, 61.8, 46.9, 34.4, 25.5. HRMS (EI) calcd for C<sub>10</sub>H<sub>13</sub>ClN [M + H] 182.0697, found 182.0696.

(*S*)-2-(4-Chlorophenyl)-pyrrolidine (*ent*-17h). Following the general procedure (GP4), the reaction of **5h** (570 mg, 2.0 mmol) with 4 M HCl solution (in dioxane, 2 mL) gives the (*S*)-2-(4-bromophenyl) pyrrolidine *ent*-17h (343 mg, 95%) as viscous oil,  $[\alpha]^{25}_{D} = -40.9$  (*c* 1.15, CH<sub>2</sub>Cl<sub>2</sub>). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)

δ ppm 7.21–7.36 (m, 4 H), 4.09 (t, J = 7.72 Hz, 1 H), 3.11–3.28 (m, 1 H), 2.85–3.08 (m, 1 H), 2.10–2.25 (m, 1 H), 1.74–1.99 (m, 3 H), 1.45–1.69 (m, 1 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ ppm 143.6, 132.2, 128.3, 127.8, 61.8, 46.9, 34.5, 25.5. HRMS (EI) calcd for C<sub>10</sub>H<sub>13</sub>ClN [M + H] 182.0731, found 182.0733.

(*R*)-2-Methyl-pyrrolidine (*ent*-171). Following the general procedure (GP4), the reaction of **51** (378 mg, 2.0 mmol) with 4 M HCl solution (in dioxane, 2 mL) gives the (*R*)-2-methyl-pyrrolidine *ent*-171 (138 mg, 92%) as viscous oil,  $[\alpha]^{25}_{D} = -31.2$  (*c* 1.19, hexane). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 2.97–3.13 (m, 2 H), 2.82 (q, J = 8.41 Hz, 1 H), 1.81–1.92 (m, 1 H), 1.66–1.82 (m, 2 H), 1.59 (br. s., 1 H), 1.18 (m and d, 4 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 54.5, 46.7, 33.7, 25.7, 21.2. HRMS (EI) calcd for C<sub>5</sub>H<sub>12</sub>N [M + H] 86.0954, found 86.0970.

(*S*)-2-Methyl-pyrolidine (171). Following the general procedure (GP4), the reaction of 4I (378 mg, 2.0 mmol) with 4 M HCl solution (in dioxane, 2 mL) gives the (*S*)-2-methyl-pyrrolidine 171 (142 mg, 95%) as viscous oil,  $[\alpha]^{25}{}_{\rm D}$  = +30.9 (*c* 1.02, hexane). <sup>1</sup>H NMR (501 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 2.97–3.13 (m, 2 H), 2.76–2.88 (m, 1 H), 1.81–1.93 (m, 1 H), 1.56–1.81 (m, 3 H), 1.07–1.25 (m, 4 H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  ppm 54.4, 46.7, 33.6, 25.6, 21.1. HRMS (EI) calcd for C<sub>5</sub>H<sub>12</sub>N [M + H] 86.0947, found 86.0970.

Acknowledgment. We thank Dr. Kapa Prasad for valuable suggestions.

**Supporting Information Available:** Complete experimental procedures, characterization data, copies of NMR spectra, and single X-ray crystallographic data for compound **4a**. This material is available free of charge via the Internet at http:// pubs.acs.org.